Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001193125-25-242555·Monte Rosa Therapeutics, Inc.
Schedule 13G ownership disclosure
Monte Rosa Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 61225M102
Event date: 2025-10-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TCG Crossover GP II, LLC
Shares: 2,213,853 · Class: 3.6%
- TCG Crossover Fund II, L.P.
Shares: 2,213,853 · Class: 3.6%
- TCG Crossover GP III, LLC
Shares: 2,213,852 · Class: 3.6%
- TCG Crossover Fund III, L.P.
Shares: 2,213,852 · Class: 3.6%
- Chen Yu
Shares: 4,427,705 · Class: 7.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-242555
- Form type
- SCHEDULE 13G
- Filer
- Monte Rosa Therapeutics, Inc.
- CIK
- CIK 1826457
- Filed
- Oct 17, 2025
- Reporting period
- Oct 10, 2025
- Description
- Schedule 13G beneficial ownership